Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease

As a result of increased prevalence of obesity worldwide, non-alcoholic fatty liver disease (NAFLD) has become one of the most common causes of chronic liver disease. Although most NAFLD cases remain benign, some progress to end-stage liver diseases such as cirrhosis and hepatocellular carcinoma. Th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yong Jiang, Tao Han, Zhi-Guang Zhang, Man Li, Feng-Xiang Qi, Ying Zhang, Ying-Lan Ji
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2017
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/a2dc2abff5b64dabb16e2113912d964a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a2dc2abff5b64dabb16e2113912d964a
record_format	dspace
spelling	oai:doaj.org-article:a2dc2abff5b64dabb16e2113912d964a2021-12-02T14:11:50ZPotential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease2095-882X10.1016/j.cdtm.2017.06.003https://doaj.org/article/a2dc2abff5b64dabb16e2113912d964a2017-09-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X16301645https://doaj.org/toc/2095-882XAs a result of increased prevalence of obesity worldwide, non-alcoholic fatty liver disease (NAFLD) has become one of the most common causes of chronic liver disease. Although most NAFLD cases remain benign, some progress to end-stage liver diseases such as cirrhosis and hepatocellular carcinoma. Therefore, treatment should be considered for NAFLD patients who are likely to progress to nonalcoholic steatohepatitis (NASH) or fibrosis. Thymosin beta 4 (TÎ²4), a G-actin sequestering peptide, regulates actin polymerization in mammalian cells. In addition, studies have reported anti-inflammatory, insulin-sensitizing, and anti-fibrotic effects of TÎ²4. However, no research has been done to investigate the effects of TÎ²4 on NAFLD. Based on the findings above mentioned, we hypothesize that TÎ²4 may represent an effective treatment for NAFLD. Keywords: Thymosin beta 4, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, HypothesisYong JiangTao HanZhi-Guang ZhangMan LiFeng-Xiang QiYing ZhangYing-Lan JiKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 3, Iss 3, Pp 165-168 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Yong Jiang Tao Han Zhi-Guang Zhang Man Li Feng-Xiang Qi Ying Zhang Ying-Lan Ji Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease
description	As a result of increased prevalence of obesity worldwide, non-alcoholic fatty liver disease (NAFLD) has become one of the most common causes of chronic liver disease. Although most NAFLD cases remain benign, some progress to end-stage liver diseases such as cirrhosis and hepatocellular carcinoma. Therefore, treatment should be considered for NAFLD patients who are likely to progress to nonalcoholic steatohepatitis (NASH) or fibrosis. Thymosin beta 4 (TÎ²4), a G-actin sequestering peptide, regulates actin polymerization in mammalian cells. In addition, studies have reported anti-inflammatory, insulin-sensitizing, and anti-fibrotic effects of TÎ²4. However, no research has been done to investigate the effects of TÎ²4 on NAFLD. Based on the findings above mentioned, we hypothesize that TÎ²4 may represent an effective treatment for NAFLD. Keywords: Thymosin beta 4, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Hypothesis
format	article
author	Yong Jiang Tao Han Zhi-Guang Zhang Man Li Feng-Xiang Qi Ying Zhang Ying-Lan Ji
author_facet	Yong Jiang Tao Han Zhi-Guang Zhang Man Li Feng-Xiang Qi Ying Zhang Ying-Lan Ji
author_sort	Yong Jiang
title	Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease
title_short	Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease
title_full	Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease
title_fullStr	Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease
title_full_unstemmed	Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease
title_sort	potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease
publisher	KeAi Communications Co., Ltd.
publishDate	2017
url	https://doaj.org/article/a2dc2abff5b64dabb16e2113912d964a
work_keys_str_mv	AT yongjiang potentialroleofthymosinbeta4inthetreatmentofnonalcoholicfattyliverdisease AT taohan potentialroleofthymosinbeta4inthetreatmentofnonalcoholicfattyliverdisease AT zhiguangzhang potentialroleofthymosinbeta4inthetreatmentofnonalcoholicfattyliverdisease AT manli potentialroleofthymosinbeta4inthetreatmentofnonalcoholicfattyliverdisease AT fengxiangqi potentialroleofthymosinbeta4inthetreatmentofnonalcoholicfattyliverdisease AT yingzhang potentialroleofthymosinbeta4inthetreatmentofnonalcoholicfattyliverdisease AT yinglanji potentialroleofthymosinbeta4inthetreatmentofnonalcoholicfattyliverdisease
_version_	1718391860675739648

Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease

Ejemplares similares